Phase 1 Specific Patient at least 18yrs of age with histologically confirmed CLL/SLL or B-cell Non-Hodgkin lymphoma (DLBCL, FL, MCL, MZL, lymphoplasmacytic lymphoma). 
Phase 2a Inclusion 
Histological evidence: FL Grade 1-3A/iNHL, with relapsed or refractory disease (iNHL includes LPL/WM, MZL); aNHL, defined as DLBCL, FL Grade 3B, MCL, and transformed NHL with relapsed disease; CLL/SLL, PTCL, or CTCL (with MF/SS) with relapsed or refractory. 
Received BCR and/or BCL2 inhibitors were intolerant or had relapsed/refractory disease afterwards. 
Prior treatment for lymphoid malignancy for progressive /refractory disease 
≥ 1 prior regimen (min 2 cycles) with antibody conjugate, cytotoxic chemotherapy, or TKI alone or in combination. 
Measureable disease defined as: ≥ 1 lesion ≥ 1.5 cm single dimension via CT, CT/PET with nodal or mass lesions; Quantifiable circulating tumor cells; or for Waldenström's macroglobulinemia presence of IgM l > 2X ULN; For CTCL: mSWAT > 0 
Ability to provide diagnostic reports 
General Inclusion 
ECOG Score of 0 or 1. 
Hematologic ANC > 1000/uL and platelet > 75,000/uL, 
Serum creatinine of < 1.5 ULN or calculated CrCl of > 50 mL/min 
Bilirubin < 20.0mg/dL (if Gilberts then < 2.5 mg/dL) and AST/AST < 2.5 ULN 

NCT01994382_inc_T1
Condition
CLL
NCT01994382_inc_T2
Condition
SLL
NCT01994382_inc_T3
Condition
B-cell Non-Hodgkin lymphoma
NCT01994382_inc_T4
Condition
DLBCL
NCT01994382_inc_T5
Condition
FL
NCT01994382_inc_T6
Condition
MCL
NCT01994382_inc_T7
Condition
MZL
NCT01994382_inc_T8
Condition
lymphoplasmacytic lymphoma
NCT01994382_inc_T9
Scope
DLBCL, FL, MCL, MZL, lymphoplasmacytic lymphoma
NCT01994382_inc_T10
Scope
CLL/SLL or B-cell Non-Hodgkin lymphoma
NCT01994382_inc_T11
Value
at least 18yrs
NCT01994382_inc_T12
Person
age
NCT01994382_inc_T13
Procedure
histologically
NCT01994382_inc_T14
Value
confirmed
NCT01994382_inc_T16
Procedure
Histological
NCT01994382_inc_T17
Condition
FL
NCT01994382_inc_T18
Measurement
Grade
NCT01994382_inc_T19
Value
1-3A
NCT01994382_inc_T20
Condition
iNHL
NCT01994382_inc_T21
Condition
refractory disease
NCT01994382_inc_T22
Condition
relapsed disease
NCT01994382_inc_T23
Condition
iNHL
NCT01994382_inc_T24
Condition
LPL
NCT01994382_inc_T25
Condition
WM
NCT01994382_inc_T26
Condition
MZL
NCT01994382_inc_T27
Scope
LPL/WM, MZL
NCT01994382_inc_T28
Scope
relapsed or refractory disease
NCT01994382_inc_T29
Condition
aNHL
NCT01994382_inc_T30
Condition
DLBCL
NCT01994382_inc_T31
Condition
FL
NCT01994382_inc_T32
Measurement
Grade
NCT01994382_inc_T33
Value
3B
NCT01994382_inc_T34
Condition
MCL
NCT01994382_inc_T35
Condition
transformed NHL
NCT01994382_inc_T36
Condition
relapsed disease
NCT01994382_inc_T37
Condition
CLL
NCT01994382_inc_T38
Condition
SLL
NCT01994382_inc_T39
Condition
PTCL
NCT01994382_inc_T40
Condition
CTCL
NCT01994382_inc_T41
Condition
MF
NCT01994382_inc_T42
Condition
SS
NCT01994382_inc_T43
Scope
MF/SS
NCT01994382_inc_T44
Scope
DLBCL, FL Grade 3B, MCL, and transformed NHL with relapsed disease
NCT01994382_inc_T45
Drug
BCL2 inhibitors
NCT01994382_inc_T46
Drug
BCR inhibitors
NCT01994382_inc_T47
Condition
intolerant
NCT01994382_inc_T48
Scope
BCR and/or BCL2 inhibitors
NCT01994382_inc_T49
Condition
relapsed
NCT01994382_inc_T50
Condition
refractory disease
NCT01994382_inc_T51
Temporal
afterwards
NCT01994382_inc_T52
Scope
relapsed/refractory disease
NCT01994382_inc_T53
Temporal
Prior
NCT01994382_inc_T54
Procedure
treatment
NCT01994382_inc_T55
Condition
lymphoid malignancy
NCT01994382_inc_T56
Condition
refractory disease
NCT01994382_inc_T57
Condition
progressive disease
NCT01994382_inc_T58
Drug
antibody conjugate
NCT01994382_inc_T59
Procedure
cytotoxic chemotherapy
NCT01994382_inc_T60
Drug
TKI
NCT01994382_inc_T61
Multiplier
≥ 1 prior regimen
NCT01994382_inc_T62
Multiplier
min 2 cycles
NCT01994382_inc_T63
Scope
antibody conjugate, cytotoxic chemotherapy, or TKI
NCT01994382_inc_T64
Condition
Measureable disease
NCT01994382_inc_T65
Multiplier
≥ 1 lesion
NCT01994382_inc_T66
Measurement
≥ 1.5 cm single dimension
NCT01994382_inc_T67
Value
≥ 1.5 cm
NCT01994382_inc_T68
Procedure
CT
NCT01994382_inc_T69
Procedure
CT/PET
NCT01994382_inc_T70
Condition
mass lesions
NCT01994382_inc_T71
Condition
nodal lesions
NCT01994382_inc_T72
Condition
circulating tumor cells
NCT01994382_inc_T73
Condition
Waldenström's macroglobulinemia
NCT01994382_inc_T74
Measurement
IgM l
NCT01994382_inc_T75
Value
> 2X ULN
NCT01994382_inc_T76
Condition
CTCL
NCT01994382_inc_T77
Measurement
mSWAT
NCT01994382_inc_T78
Value
> 0
NCT01994382_inc_T79
Scope
nodal or mass lesions
NCT01994382_inc_T80
Scope
CT, CT/PET
NCT01994382_inc_T81
Scope
≥ 1 lesion ≥ 1.5 cm single dimension via CT, CT/PET with nodal or mass lesions; Quantifiable circulating tumor cells; or for Waldenström's macroglobulinemia presence of IgM l > 2X ULN; For CTCL: mSWAT > 0
NCT01994382_inc_T84
Measurement
ECOG Score
NCT01994382_inc_T85
Value
0 or 1
NCT01994382_inc_T86
Measurement
Hematologic ANC
NCT01994382_inc_T87
Value
> 1000/uL
NCT01994382_inc_T88
Measurement
platelet
NCT01994382_inc_T89
Value
> 75,000/uL
NCT01994382_inc_T90
Measurement
Serum creatinine
NCT01994382_inc_T91
Value
< 1.5 ULN
NCT01994382_inc_T92
Measurement
calculated CrCl
NCT01994382_inc_T93
Value
> 50 mL/min
NCT01994382_inc_T94
Measurement
Bilirubin
NCT01994382_inc_T95
Value
< 20.0mg/dL
NCT01994382_inc_T96
Condition
Gilberts
NCT01994382_inc_T97
Value
< 2.5 mg/dL
NCT01994382_inc_T98
Scope
< 20.0mg/dL (if Gilberts then < 2.5 mg/dL)
NCT01994382_inc_T99
Measurement
AST/AST
NCT01994382_inc_T100
Value
< 2.5 ULN